Forest Laboratories Inc. and Forest Laboratories Holdings Ltd. announced that Forest and Royalty Pharma Collection Trust have jointly filed lawsuits in the U.S. District Court for the District of Delaware against several companies for infringement of U.S. Patent No. 6,602,911 (the “911 patent”), U.S. Patent No. 7,888,342 (the “342 patent”), and U.S. Patent No. 7,994,220 (the “220 patent”), which relate to Forest’s Savella product. Forest licenses the 911 patent, the 342 patent, and the 220 patent from Royalty Pharma. The 911 patent expires in January 2023, the 342 patent expires in November 2021, and the 220 patent expires in September 2029.
The defendants named in the lawsuits include Apotex Corp., Hetero USA Inc., Lupin Ltd., Mylan Pharmaceuticals Inc., Par Pharmaceuticals Inc., Ranbaxy Laboratories Ltd. and related companies and subsidiaries.
Forest and Royalty Pharma received notification from these companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic versions of Savella before the expiration of the various patents. The aforementioned lawsuits were commenced before the expiration of forty-five days from the date of receipt of each notification letter.
Date: September 24, 2013
Source: Forest Laboratories
